vs
Certara, Inc.（CERT）与4D Molecular Therapeutics, Inc.（FDMT）财务数据对比。点击上方公司名可切换其他公司
Certara, Inc.的季度营收约是4D Molecular Therapeutics, Inc.的1.3倍（$106.9M vs $85.1M），4D Molecular Therapeutics, Inc.净利率更高（22.8% vs -8.2%，领先31.0%），4D Molecular Therapeutics, Inc.同比增速更快（8508900.0% vs 0.8%），过去两年4D Molecular Therapeutics, Inc.的营收复合增速更高（5412.6% vs 7.0%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
4D Molecular Therapeutics是一家临床阶段生物技术企业，专注于研发靶向腺相关病毒（AAV）基因疗法，核心在研产品覆盖眼科、心脏病学、肺部疾病领域，为全球存在未满足医疗需求的罕见病和常见病患者提供新型治疗方案。
CERT vs FDMT — 直观对比
营收规模更大
CERT
是对方的1.3倍
$85.1M
营收增速更快
FDMT
高出8508899.2%
0.8%
净利率更高
FDMT
高出31.0%
-8.2%
两年增速更快
FDMT
近两年复合增速
7.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $106.9M | $85.1M |
| 净利润 | $-8.8M | $19.4M |
| 毛利率 | 61.1% | — |
| 营业利润率 | 34.9% | 17.3% |
| 净利率 | -8.2% | 22.8% |
| 营收同比 | 0.8% | 8508900.0% |
| 净利润同比 | -287.2% | 139.1% |
| 每股收益（稀释后） | $-0.06 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERTFDMT
| Q1 26 | $106.9M | — | ||
| Q4 25 | $103.6M | $85.1M | ||
| Q3 25 | $104.6M | $90.0K | ||
| Q2 25 | $104.6M | $15.0K | ||
| Q1 25 | $106.0M | $14.0K | ||
| Q4 24 | $100.4M | $1.0K | ||
| Q3 24 | $94.8M | $3.0K | ||
| Q2 24 | $93.3M | $5.0K |
净利润CERTFDMT
| Q1 26 | $-8.8M | — | ||
| Q4 25 | $-5.9M | $19.4M | ||
| Q3 25 | $1.5M | $-56.9M | ||
| Q2 25 | $-2.0M | $-54.7M | ||
| Q1 25 | $4.7M | $-48.0M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $-1.4M | $-43.8M | ||
| Q2 24 | $-12.6M | $-35.0M |
毛利率CERTFDMT
| Q1 26 | 61.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率CERTFDMT
| Q1 26 | 34.9% | — | ||
| Q4 25 | 0.8% | 17.3% | ||
| Q3 25 | 2.9% | -67983.3% | ||
| Q2 25 | 9.1% | -396373.3% | ||
| Q1 25 | 7.2% | -383007.1% | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 2.7% | -1704400.0% | ||
| Q2 24 | -9.7% | -849120.0% |
净利率CERTFDMT
| Q1 26 | -8.2% | — | ||
| Q4 25 | -5.7% | 22.8% | ||
| Q3 25 | 1.5% | -63195.6% | ||
| Q2 25 | -1.9% | -364386.7% | ||
| Q1 25 | 4.5% | -342657.1% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | -1.4% | -1461433.3% | ||
| Q2 24 | -13.5% | -699060.0% |
每股收益（稀释后）CERTFDMT
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $-0.04 | $0.43 | ||
| Q3 25 | $0.01 | $-1.01 | ||
| Q2 25 | $-0.01 | $-0.98 | ||
| Q1 25 | $0.03 | $-0.86 | ||
| Q4 24 | $0.04 | — | ||
| Q3 24 | $-0.01 | $-0.79 | ||
| Q2 24 | $-0.08 | $-0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.5M | $402.7M |
| 总债务越低越好 | $3.0M | — |
| 股东权益账面价值 | $1.0B | $505.7M |
| 总资产 | $1.5B | $566.7M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资CERTFDMT
| Q1 26 | $149.5M | — | ||
| Q4 25 | $189.4M | $402.7M | ||
| Q3 25 | $172.7M | $305.1M | ||
| Q2 25 | $162.3M | $293.2M | ||
| Q1 25 | $179.1M | $321.4M | ||
| Q4 24 | $179.2M | $424.9M | ||
| Q3 24 | $233.0M | $501.9M | ||
| Q2 24 | $224.6M | $541.9M |
总债务CERTFDMT
| Q1 26 | $3.0M | — | ||
| Q4 25 | $293.1M | — | ||
| Q3 25 | $293.5M | — | ||
| Q2 25 | $294.2M | — | ||
| Q1 25 | $294.8M | — | ||
| Q4 24 | $295.4M | — | ||
| Q3 24 | $296.1M | — | ||
| Q2 24 | $296.7M | — |
股东权益CERTFDMT
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.1B | $505.7M | ||
| Q3 25 | $1.1B | $369.0M | ||
| Q2 25 | $1.1B | $420.9M | ||
| Q1 25 | $1.1B | $469.7M | ||
| Q4 24 | $1.1B | $510.6M | ||
| Q3 24 | $1.1B | $552.9M | ||
| Q2 24 | $1.0B | $588.3M |
总资产CERTFDMT
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.6B | $566.7M | ||
| Q3 25 | $1.5B | $424.0M | ||
| Q2 25 | $1.5B | $473.6M | ||
| Q1 25 | $1.6B | $515.7M | ||
| Q4 24 | $1.6B | $560.4M | ||
| Q3 24 | $1.5B | $604.0M | ||
| Q2 24 | $1.5B | $620.1M |
负债/权益比CERTFDMT
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.7M | $28.6M |
| 自由现金流经营现金流 - 资本支出 | — | $28.5M |
| 自由现金流率自由现金流/营收 | — | 33.5% |
| 资本支出强度资本支出/营收 | 0.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.47× |
| 过去12个月自由现金流最近4个季度 | — | $-109.9M |
8季度趋势，按日历期对齐
经营现金流CERTFDMT
| Q1 26 | $11.7M | — | ||
| Q4 25 | $28.8M | $28.6M | ||
| Q3 25 | $32.3M | $-46.5M | ||
| Q2 25 | $17.8M | $-43.4M | ||
| Q1 25 | $17.4M | $-47.8M | ||
| Q4 24 | $49.4M | $-134.6M | ||
| Q3 24 | $17.0M | $-29.4M | ||
| Q2 24 | $9.8M | $-30.2M |
自由现金流CERTFDMT
| Q1 26 | — | — | ||
| Q4 25 | $27.8M | $28.5M | ||
| Q3 25 | $32.1M | $-46.6M | ||
| Q2 25 | $17.8M | $-43.4M | ||
| Q1 25 | $16.8M | $-48.4M | ||
| Q4 24 | $49.0M | $-138.4M | ||
| Q3 24 | $16.8M | $-31.2M | ||
| Q2 24 | $9.4M | $-30.6M |
自由现金流率CERTFDMT
| Q1 26 | — | — | ||
| Q4 25 | 26.8% | 33.5% | ||
| Q3 25 | 30.7% | -51765.6% | ||
| Q2 25 | 17.0% | -289620.0% | ||
| Q1 25 | 15.8% | -345635.7% | ||
| Q4 24 | 48.8% | -13837100.0% | ||
| Q3 24 | 17.7% | -1038966.7% | ||
| Q2 24 | 10.1% | -611840.0% |
资本支出强度CERTFDMT
| Q1 26 | 0.6% | — | ||
| Q4 25 | 1.0% | 0.1% | ||
| Q3 25 | 0.2% | 101.1% | ||
| Q2 25 | 0.1% | 440.0% | ||
| Q1 25 | 0.6% | 4507.1% | ||
| Q4 24 | 0.4% | 378600.0% | ||
| Q3 24 | 0.2% | 59266.7% | ||
| Q2 24 | 0.5% | 6980.0% |
现金转化率CERTFDMT
| Q1 26 | — | — | ||
| Q4 25 | — | 1.47× | ||
| Q3 25 | 21.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.66× | — | ||
| Q4 24 | 7.51× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
